Introduction
Despite widespread use of second-generation cholinesterase inhibitors for the symptomatic treatment of Alzheimer's disease (AD), little is known about the long term effects of choliner READ MORE http://alzres.com/content/6/4/48/abstract
The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day d READ MORE http://alzres.com/content/pdf/alzrt166.pdf
Objective: Switching patients with Alzheimer's disease from one cholinesterase inhibitor to another represents a viable option for patients not responding to current therapy. The objective of this lar READ MORE http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528233/
Summary: Rivastigmine is beneficial for people with Alzheimer's disease.
Alzheimer's disease (AD) is the commonest cause of dementia affecting older people, and is associated with loss of cholinerg READ MORE http://www.cochrane.org/reviews/en/ab001191.html
Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?
Seltzer B.
The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine are th READ MORE http://www.ncbi.nlm.nih.gov/pubmed/17953456
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Bullock R, Dengiz A.
The cholinesterase inhibitors (ChE-Is)--rivastigmine, donep READ MORE http://www.ncbi.nlm.nih.gov/pubmed/15963209
The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort
Pearl Behl, Krista L. Lanc READ MORE http://journals.cambridge.org/action/displayAbstract...
CHICAGO -- July 29, 2008 -- Patients with early Alzheimer's disease who are being treated with an acetylcholinesterase inhibitor have better motor vehicle driving skills compared with those who are no READ MORE http://www.pslgroup.com/dg/2269b6.htm
Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.
Pola R, Flex A, Ciaburri M, Rovella E, Valiani A, Reali G, Si READ MORE http://www.ncbi.nlm.nih.gov/pubmed/15925115
Management of Alzheimer's Disease: Assessing the Effects of Cholinesterase Inhibitors
(From: The Canadian Journal of Diagnosis, Vol. 20, No. 6, p. 49-52.)
Editorial Consultant
Bernard Groulx, M READ MORE http://www.acc.gc.ca/print.cfm...
Cholinesterase inhibitors stabilize Alzheimer's disease.
Giacobini E.
University Hospitals of Geneva, Department of Geriatrics, University of Geneva, Medical School, CH-1226 Thonex, Geneva READ MORE http://www.ncbi.nlm.nih.gov/pubmed/11193171
The Management of Alzheimer's Disease and Related Dementias: Part 2 -- The Role of Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease and Related Dementias
Steven G. Potkin, MD
Co READ MORE http://cme.medscape.com/viewarticle/467554_1
Abstract: Alzheimer's disease is characterized by progressive cognitive and functional decline and the emergence of behavioral disturbances. Behavioral symptoms, in particular, cause great distress READ MORE http://www.pubmedcentral.nih.gov/articlerender.fcgi...
10 Dec 2008: Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer's disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dem READ MORE http://www.medicalnewstoday.com/articles/132476.php
SUMMARY
Cholinesterase inhibitors (ChEIs), donepezil, galantamine and rivastigmine are efficacious for mild to moderate Alzheimer's disease
Alzheimer's disease is the commonest cause of dementia READ MORE http://www.cochrane.org/reviews/en/ab005593.html
Four cholinesterase inhibitors have been approved by the FDA for treating Alzheimer's. Three of these are often prescribed: Aricept (donepezil), Razadyne (galantamine), and Exelon (rivastigmine). The fourth, Cognex (tacrine) is rarely prescribed nowadays, due to its liver toxicity.